Меню
Идёт набор NCT06408584

Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab

— Наблюдательное Esophageal Squamous Cell Carcinoma

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Esophageal Squamous Cell Carcinoma. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab in Patients With Region-relapsed or Progressive Esophageal Squamous Cell Carcinoma: a Single Arm, Observational Study

Обзор

The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced esophageal squamous cell carcinoma.

Первичные конечные точки

  • PFS [Срок оценки: 1 month post treatment]]
Вторичные конечные точки (2)
  • ORR [Срок оценки: 1 month post treatment]]
  • 1，3-year overall survival, Adverse effect [Срок оценки: 1 month post treatment]]

Критерии участия

Критерии включения

  • Signing informed consent; ECOG 0-2 points;
  • Age over 18 years old, gender is not limited;
  • Esophageal squamous cell carcinoma confirmed by pathology or clinically diagnosed by imaging;
  • Recurrence of the tumor area after radical surgery or radical chemoradiotherapy; Regional progression of advanced esophageal squamous cell carcinoma after first-line or second-line treatment;
  • Clinical staging: regional recurrence (rT0-4N0-3M0-1a) or regional progression (cT0-4N0-3M0-1) (AJCC/UICC esophageal cancer staging (8th edition));
  • Tumor lesions can be evaluated;
  • Expected survival ≥3 months;
  • Major organ function is normal, meeting the following criteria: (i) blood routine examination A.HB ≥90g/L; b.ANC≥1.5×109/L; C. PLT ≥80×109/L; (ii) Biochemical examination: a. ALT/AST≤2.5ULN; b. TBIL≤1.5ULN; c. Plasma Cr≤1.5ULN or creatinine clearance (CCr)≥60ml/min;
  • Women of childbearing age must have had a pregnancy within 7 days before starting treatment and the result is negative;
  • All enrolled patients should take adequate contraceptive measures throughout the treatment period and 4 weeks after completion;
  • no serious hematopoietic function, heart function, endocrine and immune function defects;
  • No patients with grade 3 or above other serious medical diseases.

Критерии исключения

  • Under 18 years of age; ECOG is greater than 2;
  • The diagnosis of esophageal cancer is not supported by pathological biopsy or image examination;
  • Salvage surgery was performed after tumor recurrence;
  • The patient has any active autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; The patient had vitiligo; Those with complete remission of asthma in childhood can be included without any intervention in adulthood; Patients with asthma requiring medical intervention with bronchodilators are not included);
  • Patients who were taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes (doses \>10mg/ day of prednisone or other therapeutic hormones) and continued to use within 2 weeks before enrollment;
  • Patients with severe and/or uncontrolled concomitant disease of grade 3 or higher, including: poor blood pressure control, myocardial ischemia or myocardial infarction, arrhythmia, active or uncontrolled severe infection; Liver diseases such as decompensated liver disease, active hepatitis B (HBV-DNA≥104 copy numbers /ml or 2000IU/ml), or hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower detection limit of analytical methods);
  • Pregnant or lactating women;
  • Patients who have a history of psychotropic drug abuse and cannot quit or have mental disorders;
  • Patients who have participated in clinical trials of other drugs within four weeks; .Patients or family members refused to participate in the study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Китай · 1 центр
  • Yuan He — Хэфэй

Идентификаторы

NCT: NCT06408584 · 2024-ky117

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗